<h3>申请 TipRanks 高级版 70% 折扣</h3>
<ul>
<li>解锁对冲基金级别的数据和强大的投资工具，以做出更聪明、更精准的决策</li>
<li>通过最新的新闻和分析保持市场领先，最大化您的投资组合潜力</li>
</ul>
<p>AFT Pharmaceuticals Ltd.（（AU:AFP））的最新动态现已发布。</p>
<p>AFT Pharmaceuticals 在新西兰获得了有利的上诉法院判决，驳回了 PBL Solutions 对 AFT 的外用皮肤药物 Pascomer 在治疗葡萄酒色斑（非孤儿适应症）使用的利润分成的索赔。该裁决确认与 PBL 的利润分享仅限于 Pascomer 的孤儿药申请，且上诉费用由双方分担，AFT 不预计对其 2026 财年收益指引产生重大影响，进一步增强了对未来来自潜在更大非孤儿市场的经济确定性。</p>
<p>争议的核心在于 PBL 作为 AFT Orphan Pharmaceuticals 的 35% 股东，是否有权分享 Pascomer 在更广泛的非孤儿用途（超出罕见疾病适应症）的利润。通过维持早前高等法院的裁决并将非孤儿利润排除在共享池之外，该判决支持了 AFT 对更具商业意义的葡萄酒色斑机会的控制，为投资者提供了关于公司未来从该资产中获得回报的权利的清晰度。</p>
<p><strong>关于 AFT Pharmaceuticals Ltd. 的更多信息</strong></p>
<p>AFT Pharmaceuticals 是一家总部位于新西兰的跨国制药公司，开发、营销和分销广泛的专有和许可药物组合，涵盖非处方药、处方药和医院渠道。其产品包括专利药、品牌药和仿制药，销售于澳大利亚、新西兰、部分亚洲、北美和欧洲等核心市场，且通过外部许可协议将其覆盖范围扩展至超过 125 个国家。</p>
<p><strong>平均交易量：</strong> 1,508</p>
<p><strong>技术情绪信号：</strong> 强烈买入</p>
<p><strong>当前市值：</strong> 3.077 亿澳元</p>
<p>要全面评估 AFP 股票，请访问 TipRanks 的股票分析页面。</p>

福泰制药

ATYR

<p>AFT 制药公司在新西兰赢得了一项上诉法院的裁决，驳回了 PBL Solutions 对其皮肤药物 Pascomer 在非孤儿适应症使用中利润分成的索赔。该判决确认利润分成仅限于孤儿药申请，确保 AFT 在更有利可图的葡萄酒污渍市场中保持控制。AFT 预计对其 2026 财年的收益指引不会产生重大影响，为投资者提供了关于该资产未来回报的清晰信息</p>

<h3>Claim 70% Off TipRanks Premium</h3>
<div class="lb-trans"><h3>申请 TipRanks 高级版 70% 折扣</h3>
</div><ul>
<li>Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions</li>
<li>Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential</li>
</ul>
<div class="lb-trans"><ul>
<li>解锁对冲基金级别的数据和强大的投资工具，以做出更聪明、更精准的决策</li>
<li>通过最新的新闻和分析保持市场领先，最大化您的投资组合潜力</li>
</ul>
</div><p>An update from AFT Pharmaceuticals Ltd. ( (AU:AFP) ) is now available.</p>
<div class="lb-trans"><p>AFT Pharmaceuticals Ltd.（（AU:AFP））的最新动态现已发布。</p>
</div><p>AFT Pharmaceuticals has secured a favourable Court of Appeal judgment in New Zealand, which dismissed a claim by PBL Solutions for a share of any profits from the use of AFT’s topical skin medicine Pascomer in treating Port Wine Stains, a non-orphan indication. The ruling confirms that profit-sharing with PBL remains limited to orphan drug applications of Pascomer, with costs of the appeal shared, and AFT does not expect any material impact on its FY 2026 earnings guidance, reinforcing certainty over future economics from a potentially much larger non-orphan market.</p>
<div class="lb-trans"><p>AFT Pharmaceuticals 在新西兰获得了有利的上诉法院判决，驳回了 PBL Solutions 对 AFT 的外用皮肤药物 Pascomer 在治疗葡萄酒色斑（非孤儿适应症）使用的利润分成的索赔。该裁决确认与 PBL 的利润分享仅限于 Pascomer 的孤儿药申请，且上诉费用由双方分担，AFT 不预计对其 2026 财年收益指引产生重大影响，进一步增强了对未来来自潜在更大非孤儿市场的经济确定性。</p>
</div><p>The dispute centred on whether PBL, a 35% shareholder in AFT Orphan Pharmaceuticals, was entitled to share in profits from broader, non-orphan uses of Pascomer beyond rare-disease indications. By upholding the earlier High Court decision and keeping non-orphan profits outside the shared pool, the judgment supports AFT’s control over the more commercially significant Port Wine Stain opportunity, providing clarity for investors on the company’s rights to future returns from this asset.</p>
<div class="lb-trans"><p>争议的核心在于 PBL 作为 AFT Orphan Pharmaceuticals 的 35% 股东，是否有权分享 Pascomer 在更广泛的非孤儿用途（超出罕见疾病适应症）的利润。通过维持早前高等法院的裁决并将非孤儿利润排除在共享池之外，该判决支持了 AFT 对更具商业意义的葡萄酒色斑机会的控制，为投资者提供了关于公司未来从该资产中获得回报的权利的清晰度。</p>
</div><p><strong>More about AFT Pharmaceuticals Ltd.</strong></p>
<div class="lb-trans"><p><strong>关于 AFT Pharmaceuticals Ltd. 的更多信息</strong></p>
</div><p>AFT Pharmaceuticals is a New Zealand-based multinational pharmaceutical company that develops, markets and distributes a broad portfolio of proprietary and in-licensed medicines across over-the-counter, prescription and hospital channels. Its products, including patented, branded and generic drugs, are sold in core markets such as Australia, New Zealand, parts of Asia, North America and Europe, with out-licensing agreements extending its reach to more than 125 countries.</p>
<div class="lb-trans"><p>AFT Pharmaceuticals 是一家总部位于新西兰的跨国制药公司，开发、营销和分销广泛的专有和许可药物组合，涵盖非处方药、处方药和医院渠道。其产品包括专利药、品牌药和仿制药，销售于澳大利亚、新西兰、部分亚洲、北美和欧洲等核心市场，且通过外部许可协议将其覆盖范围扩展至超过 125 个国家。</p>
</div><p><strong>Average Trading Volume:</strong> 1,508</p>
<div class="lb-trans"><p><strong>平均交易量：</strong> 1,508</p>
</div><p><strong>Technical Sentiment Signal:</strong> Strong Buy</p>
<div class="lb-trans"><p><strong>技术情绪信号：</strong> 强烈买入</p>
</div><p><strong>Current Market Cap:</strong> A$307.7M</p>
<div class="lb-trans"><p><strong>当前市值：</strong> 3.077 亿澳元</p>
</div><p>For a thorough assessment of AFP stock, go to TipRanks’ Stock Analysis page.</p>
<div class="lb-trans"><p>要全面评估 AFP 股票，请访问 TipRanks 的股票分析页面。</p>
</div>

AFT 制药在 Pascomer 利润分成争议中赢得上诉